SCHEMBL3347712

SCHEMBL3347712

NCCCCSSCCCCN

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NFKB1 P19838 1/20 0.54
TSHR P16473 4/20 0.53
THPO P40225 2/20 0.53
DNM1 Q05193 6/20 0.50
CA12 O43570 3/20 0.50
CA1 P00915 3/20 0.50
CA2 P00918 3/20 0.50
CA3 P07451 3/20 0.50
CA4 P22748 3/20 0.50
CA6 P23280 3/20 0.50
CA5A P35218 3/20 0.50
CA7 P43166 3/20 0.50
CA9 Q16790 3/20 0.50
CA14 Q9ULX7 3/20 0.50
CA5B Q9Y2D0 3/20 0.50
MAPT P10636 2/20 0.50
EHMT2 Q96KQ7 1/20 0.50
TDP1 Q9NUW8 1/20 0.50
LMNA P02545 1/20 0.50
BLM P54132 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3346776 0.96 DNM1 (0.57) NFKB1TSHRTHPODNM1CA12
SCHEMBL3355384 0.96 DNM1 (0.57) NFKB1TSHRTHPODNM1CA12
SCHEMBL3350152 0.96 DNM1 (0.57) NFKB1TSHRTHPODNM1CA12
SCHEMBL3348447 0.96 DNM1 (0.57) NFKB1TSHRTHPODNM1CA12
Hydrochloric Acid SCHEMBL6832653 0.96 MAPT (0.56) NFKB1TSHRTHPODNM1CA12
SCHEMBL3350257 0.96 DNM1 (0.57) NFKB1TSHRTHPODNM1CA12
Hydrochloric Acid SCHEMBL5325306 0.93 DNM1 (0.53) NFKB1TSHRTHPODNM1CA12
Hydrochloric Acid SCHEMBL10810690 0.93 DNM1 (0.53) NFKB1TSHRTHPODNM1CA12
Hydrochloric Acid SCHEMBL10809136 0.93 DNM1 (0.53) NFKB1TSHRTHPODNM1CA12
Hydrochloric Acid SCHEMBL10808301 0.93 DNM1 (0.53) NFKB1TSHRTHPODNM1CA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150150994-A1 LIVER TARGETED DRUG DELIVERY SYSTEMS USING METAL NANOPARTICLES AND PREPARING METHOD THEREOF POSTECH ACADEMY-INDUSTRY FOUNDATION (KR) 2015-06-04 US claimed
US-11718698-B2 Polyolefin grafted polydiene polymers, and methods of making and using same BRIDGESTONE CORPORATION (JP) 2023-08-08 US disclosed
US-20210230420-A1 Polyolefin Grafted Polydiene Polymers, And Methods Of Making And Using Same BRIDGESTONE CORPORATION (JP) 2021-07-29 US disclosed
EP-3397666-B1 POLYOLEFIN GRAFTED POLYDIENE POLYMERS, AND METHODS OF MAKING AND USING SAME BRIDGESTONE CORP (JP) 2020-08-26 EP disclosed
CN-108473635-B Polyolefin grafted polydiene polymers and methods of making and using the same 株式会社普利司通 2020-08-25 CN disclosed
EP-2142485-B1 METALLIC SURFACE ENHANCEMENT MACDERMID ENTHONE INC (US) 2019-07-24 EP disclosed
US-20180362695-A1 Polyolefin Grafted Polydiene Polymers, And Methods Of Making And Using Same BRIDGESTONE CORPORATION (JP) 2018-12-20 US disclosed
EP-3397666-A1 POLYOLEFIN GRAFTED POLYDIENE POLYMERS, AND METHODS OF MAKING AND USING SAME Bridgestone Corporation (JP) 2018-11-07 EP disclosed
US-10029014-B2 Synthesis of novel asymmetric bow-tie PAMAM dendrimer-based conjugates for tumor-targeting drug delivery THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) 2018-07-24 US disclosed
WO-2017117325-A1 POLYOLEFIN GRAFTED POLYDIENE POLYMERS, AND METHODS OF MAKING AND USING SAME BRIDGESTONE CORPORATION (JP) 2017-07-06 WO disclosed
US-8741390-B2 Metallic surface enhancement ENTHONE INC. (US) 2014-06-03 US disclosed
US-8323741-B2 Self assembled molecules on immersion silver coatings CITIBANK, N.A. 2012-12-04 US disclosed
US-20120276409-A1 SELF ASSEMBLED MOLECULES ON IMMERSION SILVER COATINGS ENTHONE INC. (US) 2012-11-01 US disclosed
US-8216645-B2 Self assembled molecules on immersion silver coatings ENTHONE INC. (US) 2012-07-10 US disclosed
EP-2222416-A1 SELF ASSEMBLED MOLECULES ON IMMERSION SILVER COATINGS Enthone, Inc. (US) 2010-09-01 EP disclosed
US-20100151263-A1 METALLIC SURFACE ENHANCEMENT ENTHONE INC. (US) 2010-06-17 US disclosed
EP-2142485-A1 METALLIC SURFACE ENHANCEMENT Enthone, Inc. (US) 2010-01-13 EP disclosed
US-20090121192-A1 SELF ASSEMBLED MOLECULES ON IMMERSION SILVER COATINGS ENTHONE INC. (US) 2009-05-14 US disclosed
WO-2009062139-A1 SELF ASSEMBLED MOLECULES ON IMMERSION SILVER COATINGS ENTHONE INC. (US) 2009-05-14 WO disclosed
WO-2008131206-A1 METALLIC SURFACE ENHANCEMENT ENTHONE INC. (US) 2008-10-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150150994-A1 LIVER TARGETED DRUG DELIVERY SYSTEMS USING METAL NANOPARTICLES AND PREPARING METHOD THEREOF FABP1, CD44, HDGF NFKB1 2017/4885TSHR 852/4885THPO 2745/4885
US-10029014-B2 Synthesis of novel asymmetric bow-tie PAMAM dendrimer-based conjugates for tumor-targeting drug delivery TIE1, DNM2, DNM1 NFKB1 3611/4885TSHR 2088/4885THPO 1495/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.